cladribine (leustatin) Report issue

Small molecule Orphan Drug FDA Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB
Back

Drug Pricing Summary

VA FSS

$16.9060 - $4979.7740

AUS PBS

$403.3266 - $3013.7307

Drug Product Pricing

Product $/unit Ctry. List Type
Product (units) Manufacturer
cladribine 10 mg (TABLET) $2977.0028 AUS PBS generic
  • Mavenclad (4)
    		•  Merck Healthcare Pty Ltd
    cladribine 10 mg (TABLET) $2978.7517 AUS PBS generic
  • Mavenclad (6)
    		•  Merck Healthcare Pty Ltd
    cladribine 10 mg (TABLET) $3013.7307 AUS PBS generic
  • Mavenclad (1)
    		•  Merck Healthcare Pty Ltd
    cladribine 10 mg (TABLET) $4926.7200 VA FSS
  • Mavenclad (4)
    		•  EMD Serono Inc.
    cladribine 10 mg (TABLET) $4932.9933 VA FSS
  • Mavenclad (9)
    		•  EMD Serono Inc.
    cladribine 10 mg (TABLET) $4946.9680 VA FSS
  • Mavenclad (10)
    		•  EMD Serono Inc.
    cladribine 10 mg (TABLET) $4951.5986 VA FSS
  • Mavenclad (7)
    		•  EMD Serono Inc.
    cladribine 10 mg (TABLET) $4952.0917 VA FSS
  • Mavenclad (6)
    		•  EMD Serono Inc.
    cladribine 10 mg (TABLET) $4959.2325 VA FSS
  • Mavenclad (8)
    		•  EMD Serono Inc.
    cladribine 10 mg (TABLET) $4979.7740 VA FSS
  • Mavenclad (5)
    		•  EMD Serono Inc.
    cladribine 10 mg / 10 mL (INJECTION) $403.3266 AUS PBS generic
  • Leustatin (1)
    		•  Janssen-Cilag Pty Ltd
    cladribine 10 mg / 5 mL (INJECTION) $403.3266 AUS PBS generic
  • Litak (1)
    		•  Alphapharm Pty Ltd
    cladribine 1 mg / 1 mL (1 mL INJECTION) $16.9060 VA FSS
  • Cladribine (10)
    		•  Hikma Pharmaceuticals USA Inc.
    cladribine 1 mg / 1 mL (1 mL INJECTION) $28.5730 VA FSS
  • Cladribine (10)
    		•  Fresenius Kabi, LLC

    Note: This drug pricing data is preliminary, incomplete, and may contain errors.

    Feedback

    Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

    Report issue